Back

HOPA 2021 - 17th Annual Conference of the Hematology Oncology Pharmacy Association (Virtual Meeting)

Apr 12 - Apr 17, 2021 | PortlandORUS

LARVOL is not affiliated with 17th Annual Conference of the Hematology Oncology Pharmacy Association (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners

Condition
Stage
Treatment
Setting
Biomarker
Trial Name/ID

Showing 7 abstracts linked to Trials

[VIRTUAL] Correlation of BRAF Mutation Status in Circulating Tumor DNA with Tumor Biopsy and Clinical Outcomes in the COLUMBUS Study

[VIRTUAL] Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-Label, Multicenter, Phase 1b PAVO Study

[VIRTUAL] Encorafenib plus Cetuximab, with or without Binimetinib, for BRAF V600EPositive Metastatic Colorectal Cancer: Relationship Between Carcinoembryonic Antigen and Clinical Outcomes from BEACON CRC

[VIRTUAL] In-Class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Updated Real-World Results from the Community-Based US MM-6 Study

[VIRTUAL] Results from informCLL, a Prospective Observational Registry: Prognostic Biomarker Testing, Treatment Patterns, and Dosing in 1461 Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

[VIRTUAL] Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair-Deficient or -Proficient Endometrial Cancer: Results from the GARNET Study

[VIRTUAL] Worldwide Influenza and Pneumococcal Vaccination Rates in Patients with Multiple Myeloma, and the Impact of Vaccination on Infection, Hospitalization, and Death